troubles musculosquelettiques et du tissu conjonctif
Ostéonécrose de la mâchoire d'origine médicamenteuse
Références
1.Saag KG, Petersen J, Brandi ML, et al:Romosozumaboralendronatefor fracture prevention in women with osteoporosis.N Engl J Med377(15):1417-1427, 2017. doi:10.1056/NEJMoa1708322 2.Hallmer F, Andersson G, Götrick B, et al: Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study.Oral Surg Oral Med Oral Pathol Oral Radiol126(6):477-485, 2018. doi:10.1016/j.oooo.2018.08.015 3.Masoodi NA: Oral bisphosphonates and the risk for osteonecrosis of the jawBJMP2(2):11-15, 2022. 4.Ruggiero SL, Dodson TB, Aghaloo T, et al: American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update.J Oral Maxillofac Surg80(5):920-943, 2022. doi:10.1016/j.joms.2022.02.008 5.Hellstein JW, Adler RA, Edwards B, et al: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs.J Am Dent Assoc142(11):1243−1251, 2011. doi: 10.14219/jada.archive.2011.0108 6.Khan A, Morrison A, Cheung A, et al: Osteonecrosis of the jaw (ONJ): Diagnosis and management in 2015.Osteoporos Int27(3):853–859, 2016. doi: 10.1007/s00198-015-3335-3 